Skip to main content
Premium Trial:

Request an Annual Quote

KPL Licenses Expression Pathology s Protein-Extraction Tech for Use in Upcoming Products

NEW YORK, July 21 (GenomeWeb News) - As part of a license-and-supply agreement, Kirkegaard and Perry Laboratories (KPL) has gained exclusive rights to market protein immunodetection products based on Expression Pathology's Liquid Tissue technology in the life-science research market, the companies said today in a statement.


KPL will integrate Expression Pathology's technology, which enables protein extraction from formalin-fixed paraffin-embedded tissue samples, with its own immunodetection reagents, the companies said. The products will allow customers to create reverse-phase arrays and dot blots, and to characterize and validate protein biomarkers, the companies added.


KPL said it will launch protein-extraction and -detection products resulting from the partnership "later this year."

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.